Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
An across-the-board clinical trial registry analysis spells out the effect of measures to slow the spread of the new coronavirus.
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
New consensus forecasts stretching out to 2026 see Roche easily retaining its crown as the world’s biggest drugmaker, while Bristol-Myers Squibb climbs the rankings.
170 commercial trials were suspended in March while new patient starts slumped 65% as the pandemic swept the globe. April could look even worse.
Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?